Treatment of steroid dependent asthmatics

Details Treatment of steroid dependent asthmatics Treatment of steroid dependent asthmatics

1994-01-28

1995-04-11

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514166, 514352, 514826, A61K 3157, A61K 3163, A61K 31615, A61K 3144

Patent

active

054058422

ABSTRACT:
A method for the treatment of asthma, particularly corticosteroid dependent asthma with "steroid sparing" effect, but without serious toxicities prevalent with common "steroid sparing" treatments and medications, comprising the oral administration, in efficacious doses, of sulfasalazine (SSZ) (5-([p-(2-pyridylsulfamoyl) phenyl]azo) salicylic acid) ##STR1## compounds having either the: ##STR2## moiety, or the: ##STR3## moiety. The SSZ and related compounds can be used as an adjuvant for corticosteroid treatments, which permits drastic reduction of the dosage levels of the corticosteroids with concomitant reduction of steroid side effects.

REFERENCES:
patent: 3973038 (1976-08-01), Umezawa et al.
patent: 4024253 (1977-05-01), Umezawa et al.
patent: 4091097 (1978-05-01), Umezawa et al.
patent: 5302718 (1994-04-01), Agback et al.
Derwent Abstract of Agback et al WO/PCT9310094 (May 27, 1993).
Merck Index 11th Ed. (1989) pp. 8917-8918 #8917 "Sulfasalazing".

Affiliated with

Also associated with

Rating

Treatment of steroid dependent asthmatics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of steroid dependent asthmatics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of steroid dependent asthmatics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1538601